| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c8cbbf2290b3f3a9988da29598baa2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 |
| filingDate |
2002-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58de1f251abe25beb093899a77920555 |
| publicationDate |
2003-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2003155253-A |
| titleOfInvention |
Orally administered composition for intestinal delivery and method of use thereof |
| abstract |
(57) [Problem] To provide an oral administration composition for intestinal delivery. An orally administered composition for intestinal delivery comprising: (A) a biologically active ingredient; and (B) an effective amount of occlusive zone toxin (ZOT) to promote intestinal absorption. In a preferred embodiment of the invention, in the composition for oral administration, the biologically active ingredient is selected from the group consisting of drug compounds, biologically active peptides, and vaccines. In a preferred embodiment of the invention, the ratio of biologically active ingredient to occlusive zone toxin is in the range of about 1:10 to 3: 1 in the orally administered composition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008508326-A |
| priorityDate |
1995-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |